Skip to content

Clinical trials

Observational Heart Failure trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Heart Failure Phase: Observational Country / region: Italy Clear all

144 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20041
20051
20063
20074
20082
20091
20107
20116
20125
20137
20143
20156
20167
20176
20188
20195
20206
202112
20229
202315
20246
202512
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed54
Unknown status43
Recruiting33
Active, not recruiting6
Not yet recruiting3
Terminated3
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Medtronic9
Federico II University8
Abbott Medical Devices7
Biotronik SE & Co. KG5
Fondazione Policlinico Universitario Agostino Gemelli IRCCS5
University of Campania Luigi Vanvitelli5
IRCCS Azienda Ospedaliero-Universitaria di Bologna4
IRCCS Policlinico S. Donato4
Boston Scientific Corporation3
Centro Cardiologico Monzino3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Heart Failure144
Arrhythmias, Cardiac9
Cardiomyopathies8
Bradycardia6
Cardiovascular Diseases6
Pulmonary Disease, Chronic Obstructive5
Atrial Fibrillation4
Cardiomyopathy, Dilated4
Death, Sudden, Cardiac4
Diabetes Mellitus4

Trials

Showing 1 to 25 of 144. Each trial links to its page on Pharma Observatory.

44 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.